轻松扫码查看产品文档 | TCIMAIL No.197 已上新 | TCI试剂——品质可靠，值得信赖
订购方法？联系方式：021-67121386 / Sales-CN@TCIchemicals.com
Maximum quantity allowed is 999
请选择数量
CAS RN: 129-06-6 | 产品编码: W0005
Warfarin Sodium (contains Isopropyl Alcohol)
×
![]()
×
纯度/分析方法: >98.0%(HPLC)
别名：
- 华法林钠 (含异丙醇)
- 3-(α-乙酰甲基苄基)-4-羟基香豆素钠盐 (含异丙醇)
- 4-羟基-3-(3-氧代-1-苯基丁基)香豆素钠盐 (含异丙醇)
- 3-(α-Acetonylbenzyl)-4-hydroxycoumarin Sodiuim Salt (contains Isopropyl Alcohol)
- 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin Sodium Salt (contains Isopropyl Alcohol)
产品文档：
* 点击“查询”可查看预计发货日期，仅供参考。
* 无具体发货日期的情况，如：显示“8个工作日后发货”，将在您订购日起的8个工作日后发货。
* 我们将以最优方式从上海/天津两大仓库发货。国内库存不足，需两周左右向日本总部调货。
* 对于可分装产品，11:30前的订单，当天发货；11:30后的订单，隔天发货。
* 如需大包装，请点击“大包装询价”按钮（对于某些产品我们无法提供大包装）。
* TCI会经常复审储藏条件以对其进行优化，请以在线目录为准，敬请留意。
* 更多信息，请联系营业部：021-67121386 / Sales-CN@TCIchemicals.com 。任何货期、规格或包装方面的需求，请联系我们 。
* 无具体发货日期的情况，如：显示“8个工作日后发货”，将在您订购日起的8个工作日后发货。
* 我们将以最优方式从上海/天津两大仓库发货。国内库存不足，需两周左右向日本总部调货。
* 对于可分装产品，11:30前的订单，当天发货；11:30后的订单，隔天发货。
* 如需大包装，请点击“大包装询价”按钮（对于某些产品我们无法提供大包装）。
* TCI会经常复审储藏条件以对其进行优化，请以在线目录为准，敬请留意。
* 更多信息，请联系营业部：021-67121386 / Sales-CN@TCIchemicals.com 。任何货期、规格或包装方面的需求，请联系我们 。
技术规格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 91.0 % |
| 2-Propanol | 7.0 to 9.0 % |
物性（参考值）
| 溶解性（微溶于） | 乙醚, 氯仿 |
GHS
| 象形图 |
|
| 信号词 | 危险 |
| 危险性说明 | H300 : 吞咽致命。 H360 : 可能对生育能力或胎儿造成伤害。 H370 : 会损害器官。 H372 : 长期或反复接触会对器官造成损害。 H373 : 长期或反复接触可能损害器官。 H412 : 对水生生物有害并具有长期持续影响。 |
| 防范说明 | P501 : 将内装物/容器送到批准的废物处理厂处理。 P273 : 避免释放到环境中。 P260 : 不要吸入粉尘/ 烟/ 气体/ 烟雾/ 蒸气/ 喷雾。 P270 : 使用本产品时不要进食、饮水或吸烟。 P202 : 在阅读并明了所有安全措施前切勿搬动。 P201 : 使用前取得专用说明。 P264 : 作业后彻底清洗皮肤。 P280 : 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P308+P311 : 如接触到或有疑虑：呼叫急救中心/医生。 P301 + P310 + P330 : 如误吞咽：立即呼叫急救中心/医生。漱口。 P405 : 存放处须加锁。 |
相关法规
| RTECS# | GN4725000 |
| 新化学物质备案回执号 | B1A232216184 |
运输信息
| UN编号 | UN1544 |
| 类别 | 6.1 |
| 包装类别 | II |
| 监管条件代码(*) |
应用
Warfarin Sodium (contains Isopropyl Alcohol) Binding of Warfarin to Human Serum Albumin
Warfarin is known to have affinity for Human Serum Albumin (HSA) and to bind (interact) to drug binding site I on HSA. Those were confirmed using our warfarin sodium with Surface Plasmon Resonance (SPR) and a method using fluorescent probes.
【SPR】
Dose responses of warfarin to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.
Dose responses of warfarin to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.
＜Assay condition＞
Sensor Chip: Series S Sensor Chip CM5, Immobilization: HSA (Amine Coupling method), Buffer : 5%DMSO in PBS.
＜Result＞
“Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of warfarin to HSA was confirmed.
Sensor Chip: Series S Sensor Chip CM5, Immobilization: HSA (Amine Coupling method), Buffer : 5%DMSO in PBS.
＜Result＞
“Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of warfarin to HSA was confirmed.
【Method using fluorescent probes】
The drug biding site of warfarin was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.
The drug biding site of warfarin was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.
＜Assay condition＞
Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 µM (DNSA), 20 µM (DNSG, BD140) (50 µL/well) (Fatty acid free HSA is recommended.); Warfarin: each concentration (50 µL/well); DNSA: 80 µM, DNSG: 20 µM, BD140: 20 µM (50 µL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140).
＜Result＞
As shown in upper diagram, inhibition against binding of dansylamide which is fluorescent probe for site I by warfarin was confirmed. And also, little or extremely weak inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II was confirmed.
Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 µM (DNSA), 20 µM (DNSG, BD140) (50 µL/well) (Fatty acid free HSA is recommended.); Warfarin: each concentration (50 µL/well); DNSA: 80 µM, DNSG: 20 µM, BD140: 20 µM (50 µL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140).
＜Result＞
As shown in upper diagram, inhibition against binding of dansylamide which is fluorescent probe for site I by warfarin was confirmed. And also, little or extremely weak inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II was confirmed.
In these ways, our warfarin can be used for study of interaction with HSA. Also, DNSA [D5405], DNSG [D5406] and BD140 [D4898] can be used for study of drug binding site on HSA.
References
- Fluorescent Dye Cocktail for Multiplex Drug￢Site Mapping on Human Serum Albumin
- High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE
- Biosensor Analysis of the Interaction between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels
- Characterizing a drug's primary binding site on albumin
- Structural basis of the drug-binding specificity of human serum albumin
应用
Reviews of Pharmacology of Warfarin
References
- Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol
- Systematic overview of warfarin and its drug and food interactions
- Pharmacogenetics of warfarin elimination and its clinical implications
- Pharmacogenetics of warfarin: current status and future challenges
- Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
参考文献
文章/手册
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。